KemPharm, Inc. (KMPH)
| Market Cap | 192.13M |
| Revenue (ttm) | 9.81M |
| Net Income (ttm) | -30.37M |
| Shares Out | 34.49M |
| EPS (ttm) | 0.29 |
| PE Ratio | 19.21 |
| Forward PE | 263.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 120,311 |
| Open | 5.56 |
| Previous Close | 5.62 |
| Day's Range | 5.45 - 5.58 |
| 52-Week Range | 4.00 - 10.80 |
| Beta | 2.82 |
| Analysts | Buy |
| Price Target | 19.89 (+257.1%) |
| Earnings Date | Aug 11, 2022 |
About KMPH
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CN... [Read more...]
Financial Performance
In 2021, KemPharm's revenue was $28.65 million, an increase of 115.61% compared to the previous year's $13.29 million. Losses were -$8.56 million, -32.95% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for KMPH stock is "Buy." The 12-month stock price forecast is 19.89, which is an increase of 257.09% from the latest price.
News
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercializ...
KemPharm to Report Second Quarter 2022 Financial Results
CELEBRATION, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercializ...
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
CELEBRATION, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercializ...
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercializ...
KemPharm Announces Research Affirming Serdexmethylphenidate's Lower Potential for Abuse Featured in Peer-Reviewed Pub...
Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm's prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related effects compared to d-MPH
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Orphazyme A/SCompany announcement No. 29/2022 Inside information www.orphazyme.com Company Registration No. 32266355
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased...
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPhar...
Orphazyme A/S in restructuring Company announcement No. 24/2022Inside information www.orphazyme.com Company Registration No. 32266355
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, May 12, 2022, at 5:00 p.m. ET
KemPharm to Present at Multiple Upcoming Investor Conferences
CELEBRATION, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treat...
KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hyper...
Upon IND clearance, KemPharm anticipates initiating KP1077 Phase 2 IH trial as early as the second half of 2022
KemPharm to Report First Quarter 2022 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET
KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study
KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep d...
KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil trans...
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
KemPharm to Report Fourth Quarter and Full-Year 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Idiopathic hypersomnia is an uncommon sleep disorder re...
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical...
KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD ...
Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH